None of the cell and gene therapies that reached the final regulatory submission stage were rejected by the FDA.

Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has partnered with CRISPR Therapeutics to develop CASGEVY (exagamglogene autotemcel), a gene-edited cell therapy for sickle cell disease (SCD ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

More than a year after Vertex Pharmaceuticals and CRISPR Therapeutics won FDA approval for the world’s first CRISPR edited therapy Casgevy® (“exa-cel” or exagamglogene autotemcel ...

Casgevy (exagamglogene autotemcel or exa-cel ... for TDT well ahead of the PDUFA date,” said Reshma Kewalramani, Vertex’s chief executive. “TDT patients deserve new, potentially curative ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne ...

The Medicines and Healthcare products Regulatory Agency (MHRA) cleared Vertex Pharma and CRISPR Therapeutics' Casgevy (exagamglogene autotemcel or exa-cel) in Great Britain as a one-shot therapy ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases ...